![Rebinyn® (Coagulation Factor IX [Recombinant], GlycoPEGylated)](/content/dam/biopharm/rebinyn/global/rebinyn_logo.png){kind=logo}
The World Federation of Hemophilia (WFH)e says an extended half-life prophylaxis can allow individuals to keep Factor 9 levels in the non-hemophilia range (greater than 40%) for a significant amount of time.
BE READY WITH REBINYN®
Rebinyn® helps you achieve higher factor levels so you can be ready for the unexpected.a
PREVIOUSLY TREATED ADULTS ACHIEVED FACTOR 9 LEVELS IN THE NON-HEMOPHILIA RANGE (GREATER THAN 40%)a
aData represent mean steady-state pharmacokinetic profiles from previously treated adolescent/adult patients with moderate to severe hemophilia B (n=9) taking repeated doses of Rebinyn® 40 IU/kg once weekly. Factor 9 levels were within the non-hemophilia range (greater than 40%) for 5.4 days (approximately 80% of the week).
bBased on the mean steady-state post-dose peak levels and pre-dose trough levels 168 hours after administered Rebinyn® 40 IU/kg once weekly in previously treated patients (20 adult and 9 adolescent patients).
aData represent mean steady-state pharmacokinetic profiles from previously treated adolescent/adult patients with moderate to severe hemophilia B (n=9) taking repeated doses of Rebinyn® 40 IU/kg once weekly. Factor 9 levels were within the non-hemophilia range (greater than 40%) for 5.4 days (approximately 80% of the week).
bBased on the mean steady-state post-dose peak levels and pre-dose trough levels 168 hours after administered Rebinyn® 40 IU/kg once weekly in previously treated patients (20 adult and 9 adolescent patients).
cHalf-life: Time required for Factor 9 to decline to half its value.
dBased on analysis using a 1-stage assay in patients (n=6) aged 18 and older, the half-life at steady state was 115 hours following once-weekly (40 IU/kg) dosing; in patients (n=3) aged 13 to 17, the half-life at steady state was 103 hours. Following single-dose administration (40 IU/kg) in the same patient population, the half-life was 83 hours (adults) and 89 hours (adolescents).
MAINTAINING FACTOR LEVELS BETWEEN DOSES
MAINTAINING FACTOR LEVELS BETWEEN DOSES
eWFH offers guidelines that inform shared decision-making between patients, caregivers, and healthcare providers based on data from existing peer-reviewed findings.
Timothy has severe hemophilia B and uses Rebinyn®.
fData represent mean steady-state pharmacokinetic profiles from previously treated adolescent/adult patients with moderate to severe hemophilia B (n=9) taking repeated doses of Rebinyn® 40 IU/kg once weekly. Factor 9 levels were within the non-hemophilia range (greater than 40%) for 5.4 days (approximately 80% of the week).
HIGHER LEVELS WITH REBINYN® CAN HELP KIDS BE READY FOR THE UNEXPECTED
HIGH FACTOR 9 LEVELS IN CHILDREN 12 YEARS OR YOUNGER
gMean steady-state pre-dose trough levels and post-dose peak levels across the clinical trials for all previously treated children receiving Rebinyn® 40 IU/kg once weekly. Based on an analysis using a 1-stage assay of previously treated children aged 0 to 12 years old (N=25). Children were stratified into 2 groups: ≤6 years old (n=12) and 7 to 12 years old (n=13). All patients received a fixed dose of 40 IU/kg of Rebinyn® intravenously once weekly for prophylaxis.
hBased on single-dose pharmacokinetic parameters of Rebinyn® 40 IU/kg in children aged ≤6 (n=12) and 7 to 12 years (n=13). A single-dose pharmacokinetic assessment was conducted after administration of the first dose of Rebinyn®. The last pharmacokinetic sample was collected 1 week later, just prior to administration of the second dose.
DID YOU KNOW?
Half-life is the time it takes for the level of factor in the blood to fall by half (50%).
INTERESTED IN TRYING REBINYN®?
Visit NOVOCARE.COM or call 1-844-668-6732 to speak with a NovoCare® Specialist to find out if you’re eligible to receive a limited supply of Rebinyn® for free.i Ask your doctor about the free trial offer through Novocare.com.
iPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.
PREVENT BLEEDS
WITH REBINYN®
Learn what once-weekly Rebinyn® can do for you.
CONSIDERING A SWITCH?
See how Factor 9 therapies compare on features that matter to you—from storage conditions to infusion time.
